{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Myeloma+With+Failed+Remission",
    "query": {
      "condition": "Multiple Myeloma With Failed Remission"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 5,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-07T13:33:03.475Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04184050",
      "title": "Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Myeloma in Relapse",
        "Multiple Myeloma",
        "Multiple Myeloma of Bone",
        "Multiple Myeloma With Failed Remission"
      ],
      "interventions": [
        {
          "name": "MK-4002",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2020-04-13",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-12-05",
      "last_synced_at": "2026-06-07T13:33:03.475Z",
      "location_count": 8,
      "location_summary": "Gilbert, Arizona • Phoenix, Arizona • La Jolla, California + 5 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Fairway",
          "state": "Kansas"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04184050"
    },
    {
      "nct_id": "NCT05673083",
      "title": "Impact of a Health Technology Intervention on Patient Activation in Multiple Myeloma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Myeloma in Relapse",
        "Multiple Myeloma",
        "Multiple Myeloma, Refractory",
        "Multiple Myeloma With Failed Remission"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "All4Cure",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2023-03-01",
      "completion_date": "2026-03",
      "has_results": false,
      "last_update_posted_date": "2025-09-04",
      "last_synced_at": "2026-06-07T13:33:03.475Z",
      "location_count": 7,
      "location_summary": "Fayetteville, Arkansas • Jacksonville, Florida • Des Moines, Iowa + 4 more",
      "locations": [
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Des Moines",
          "state": "Iowa"
        },
        {
          "city": "East Syracuse",
          "state": "New York"
        },
        {
          "city": "Tulsa",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05673083"
    },
    {
      "nct_id": "NCT03650491",
      "title": "A Study of FOR46 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Myeloma",
        "Multiple Myeloma in Relapse",
        "Multiple Myeloma With Failed Remission"
      ],
      "interventions": [
        {
          "name": "FOR46",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Fortis Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 31,
      "start_date": "2019-04-03",
      "completion_date": "2022-01-31",
      "has_results": false,
      "last_update_posted_date": "2022-07-27",
      "last_synced_at": "2026-06-07T13:33:03.475Z",
      "location_count": 7,
      "location_summary": "San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 4 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03650491"
    },
    {
      "nct_id": "NCT03687125",
      "title": "Tinostamustine Conditioning and Autologous Stem Cell",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma in Relapse",
        "Multiple Myeloma Progression",
        "Multiple Myeloma With Failed Remission"
      ],
      "interventions": [
        {
          "name": "Tinostamustine",
          "type": "DRUG"
        },
        {
          "name": "Autologous Stem Cell Transplant (ASCT)",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Mundipharma-EDO GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 6,
      "start_date": "2018-10-15",
      "completion_date": "2019-04-17",
      "has_results": true,
      "last_update_posted_date": "2021-06-18",
      "last_synced_at": "2026-06-07T13:33:03.475Z",
      "location_count": 7,
      "location_summary": "Birmingham, Alabama • Kansas City, Kansas • New York, New York + 4 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03687125"
    },
    {
      "nct_id": "NCT01174082",
      "title": "Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma Relapsing or Failing to Achieve a Complete Remission After an Allogenic Transplant",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myeloma"
      ],
      "interventions": [
        {
          "name": "KLH Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "KLH-id Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GM-CSF",
          "type": "DRUG"
        },
        {
          "name": "Apheresis",
          "type": "PROCEDURE"
        },
        {
          "name": "Donor Lymphocyte Infusion (DLI)",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 2,
      "start_date": "2010-07-20",
      "completion_date": "2017-02-23",
      "has_results": true,
      "last_update_posted_date": "2018-06-01",
      "last_synced_at": "2026-06-07T13:33:03.475Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01174082"
    }
  ]
}